Advertisement

Medical Oncology

, 35:121 | Cite as

Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study

  • Rosario Mazzola
  • Sergio Fersino
  • Giuseppe Ferrera
  • Giovanni Targher
  • Vanessa Figlia
  • Luca Triggiani
  • Nadia Pasinetti
  • Antonio Lo Casto
  • Ruggero Ruggieri
  • Stefano Maria Magrini
  • Filippo Alongi
Original Paper
  • 90 Downloads

Abstract

To analyze the impact of SBRT on systemic treatment-free survival in patients affected by lung oligometastases. Inclusion criteria of the study were (a) KPS > 70, (b) 1–5 lung oligometastases underwent SBRT with a BED ≥ 100 Gy, (c) absence of extra-thoracic disease, (d) controlled primary tumor, (e) metachronous oligorecurrences for whom SBRT was adopted as primary treatment option, (f) oligoprogressive lung metastases who progressed following a disease remission after a first-line therapy, (g) oligopersistent disease after systemic therapy, and (h) at least 6 months of follow-up post-SBRT. Primary study endpoint was the systemic treatment-free survival for each group, whereas distant progression-free survival (DPFS), local failure-free survival (LFFS), and overall survival (OS) were the secondary endpoints. Seventy-eight patients and 114 lung metastases were analyzed. Of these, 32 patients were treated with SBRT in the oligorecurrence group, whereas the remaining patients underwent SBRT for oligoprogressive disease (n = 35) oligopersistent disease (n = 11). In the whole cohort of patients, the median systemic treatment-free survival was 16 months (3–46 months), the median LFFS was 18 months (12–46 months), the median DPFS was 14 months (3–43 months), and the median OS was 19.6 months (12–47 months). Oligorecurrence group had better clinical outcomes in terms of systemic treatment-free survival (log-rank test p = 0.0035) and DPFS (log-rank test p = 0.0017) compared to the other groups. In the present experience, SBRT allowed to delay the administration of systemic treatments in several settings of lung oligometastasis.

Keywords

SBRT Lung oligometastases Systemic therapy Oligometastases Radiotherapy 

Notes

Funding

No funding support the present study.

Compliance with ethical standards

Conflict of interest

The Authors declare no conflict of interest.

References

  1. 1.
    Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10.CrossRefPubMedGoogle Scholar
  2. 2.
    Alongi F, Arcangeli S, Filippi AR, et al. Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist. 2012;17(8):1100–7.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Guckenberger M. Oligoprogression. Strahlenther Onkol. 2015;191(5):453–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Shultz DB, Filippi AR, Thariat J, et al. Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer. J Thorac Oncol. 2014;9(10):1426–33.CrossRefPubMedGoogle Scholar
  5. 5.
    Alongi F, Mazzola R, Figlia V, Guckenberger M. Stereotactic body radiotherapy for lung oligometastases: literature review according to PICO criteria. Tumori J. 2018;1:300891618766820.Google Scholar
  6. 6.
  7. 7.
    Grimm J, LaCouture T, Croce R, et al. Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy. J Appl Clin Med Phys. 2011;12(2):3368.CrossRefPubMedGoogle Scholar
  8. 8.
    Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S-50S.PubMedGoogle Scholar
  9. 9.
    Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;83(3):878–86.CrossRefPubMedGoogle Scholar
  10. 10.
    Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113(1):37–49.CrossRefPubMedGoogle Scholar
  11. 11.
    de Baère T, Aupérin A, Deschamps F, et al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol. 2015;26(5):987–91.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Mazzola R, Fiorentino A, Di Paola G, et al. Stereotactic ablative radiation therapy for lung oligometastases: predictive parameters of early response by 18FDG-PET/CT. J Thorac Oncol. 2017;12(3):547–55.CrossRefPubMedGoogle Scholar
  13. 13.
    Takeda A, Kunieda E, Ohashi T, et al. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol. 2011;101:255–9.CrossRefPubMedGoogle Scholar
  14. 14.
    McCammon R, Schefter TE, Gaspar LE, et al. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2009;73:112–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Milano MT, Katz AW, Schell MC, et al. Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72:1516–22.CrossRefPubMedGoogle Scholar
  16. 16.
    Hoerner-Rieber J, Duma M, Blanck O, et al. Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma-a multicenter analysis of the German working group “Stereotactic Radiotherapy”. J Thorac Dis. 2017;9(11):4512–22.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Rosario Mazzola
    • 1
  • Sergio Fersino
    • 1
  • Giuseppe Ferrera
    • 2
  • Giovanni Targher
    • 3
  • Vanessa Figlia
    • 1
  • Luca Triggiani
    • 4
  • Nadia Pasinetti
    • 4
  • Antonio Lo Casto
    • 5
  • Ruggero Ruggieri
    • 1
  • Stefano Maria Magrini
    • 4
  • Filippo Alongi
    • 1
    • 6
  1. 1.Radiation OncologyIRCCS Sacro Cuore Don Calabria HospitalNegrar-VeronaItaly
  2. 2.Radiation OncologyARNAS CivicoPalermoItaly
  3. 3.Section of Endocrinology, Diabetes and Metabolism, Department of MedicineUniversity and Azienda Ospedaliera Universitaria Integrata of VeronaVeronaItaly
  4. 4.Radiation OncologyUniversity and Spedali Civili HospitalBresciaItaly
  5. 5.Sezione di Scienze Radiologiche, DIBIMEDUniversità di PalermoPalermoItaly
  6. 6.University of BresciaBresciaItaly

Personalised recommendations